Mon, 02 Nov 2026
Pharma in Focus

Connecting you with your industry every day

Featured

Federal Court slaps company with $6.5M fine

Ruling in favour of the TGA in its case against a company which unlawfully advertised prescription-only medicines, which the judge described as a "deliberate commercial strategy"

Regulatory & Reimbursement

Aussies continue FDA winning streak

Melbourne-based pharma notches another win in the US with the granting of an Orphan Drug designation, marking an important commercial milestone

Leadership & People

Ex-Novartis GM snapped up for global role

So that's where he's gone... Well-known Aussie pharma exec has been tapped for a global position, joining a new company at a time of significant growth

Government & Policy

AbbVie pitches a world-class PBS

As concerns grow over Australia’s lagging access to medicines, AbbVie has released a report exposing just how far the country has fallen behind and who is paying the price

Latest News
More News
Regulatory & Reimbursement

Three pharmas hit with first rival

The TGA has approved the first copycats of long-standing drugs sponsored by Bayer, Link Medical Products, and Novo in Australia

Regulatory & Reimbursement

Is the era of rising drug prices over?

The prices of new drugs at launch rose by over a third from 2022 to 2025, but the trend came to an abrupt end in the last year. Is this the start of a new era?

Latest

Health leaders of tomorrow start here

AbbVie helps inspire the next generation of changemakers by backing the Future Health Leaders Program alongside Research Australia and the CSIRO

Earlier News
Government & Policy

Guild turns up heat on PBS prices

New poll puts pressure on Govt to freeze the PBS co-pay at $25 amid a cost-of-living crisis, just a couple of months out from a scheduled price hike

Pipeline & Intellectual Property

Six-way legal stoush over $47.5M market

J&J has started proceedings to prevent four companies from launching generic versions of one of its drugs, but a fifth decided it also wanted to get involved

Patients

Patients pick favourite pharma

One company shot up the rankings by four places to be declared the top Big Pharma when it comes to corporate reputation, judged by diabetes patients

Popular
Featured

MA lands its 50th member

A new member of Medicines Australia has seen the ranks of the industry organisation swell to 50

Pipeline & Intellectual Property

CEO stands by takeover despite US$1.9B hit

Insists the phase 3 fail of one of the deal's key assets is just a “bump” for the company and the price of pioneering science

Pipeline & Intellectual Property

Astellas bets $1.89B on Aussie drug

Astellas Pharma has agreed to pay up to $1.89 billion for rights to develop and commercialise a pre-clinical immuno-oncology candidate

More News
Industry & Companies

Top pharma employers as voted by staff

Twelve pharmas made the Top 20 science-focused companies to work for list, voted in by the people who work there. See who made the cut

Leadership & People

Ex-Aussie GM lands top new role

Less than three years after leaving Australia, this leader who spent five years heading the ANZ team has won another promotion

All positions →

Jobs

  1. Order Management Officer New

    HPGEast RydeSales
  2. WHS and Wellbeing Lead New

    HPGNew South WalesOther
  3. Warehouse Assistant New

    HPGMascotOther
  4. Specialty Care Consultant New

    HPGSydneySales
  5. Territory Manager - Surgical Devices New

    HPGSydneySales
  6. Commercial Excellence Analyst New

    HPGSydneyOther
  7. Territory Manager New

    HPGNewcastleSales
Popular

Dept boasts faster medicines access

Annual Report hails 100 per cent strike rate on six-months-to-listing target but the fine print reveals the numbers don't tell the full story

Other News
Industry & Companies

Is pharma finally in a good mood?

The bright future pharma has been dreaming of has arrived... at least for some with positive sentiment on a steep climb - except when it comes to the prospect of finding a new job

Industry & Companies

CSL grilled by many cooks

Shareholders turned up the heat at the company's AGM this morning, with the outgoing Chair conceding it had overpaid for an US$11.7B acquisition

Pipeline & Intellectual Property

Cancer drug's 'unprecedented' trial results

Slashes the risk of death by 58% in this lung cancer patient cohort, with the company describing the findings as a watershed moment in the management of the disease

In Case You Missed It
Regulatory & Reimbursement

Four pharmas start run for Govt funding

A company navigating Australia's reimbursement system for the first time is kicking off the race for Government funding

More News